Recent trends in the number of pathology samples indicating cancer in Northern Ireland

November 2020 Update

Acknowledgements: The Northern Ireland Cancer Registry (NICR) is funded by the Public Health Agency. NICR uses data provided by patients and collected by the health service as part of their care and support.








Contents

	Page
Summary	3
Number of pathology samples indicating cancer - All persons	5
Number of pathology samples indicating cancer - Males	7
Number of pathology samples indicating cancer - Females	9
Number of pathology samples indicating cancer - Ages 0-69	11
Number of pathology samples indicating cancer - Ages 70 and over	13
Number of pathology samples indicating cancer - Belfast	15
Number of pathology samples indicating cancer - Altnagelvin	17
Number of pathology samples indicating cancer - Antrim	19
Number of pathology samples indicating cancer - Craigavon	21
Number of pathology samples indicating bowel cancer - All persons	23
Number of pathology samples indicating bowel cancer - All persons, screening age	25
Number of pathology samples indicating lung cancer - All persons	27
Number of pathology samples indicating breast cancer - Females	29
Number of pathology samples indicating breast cancer - Females, screening age	31
Number of pathology samples indicating prostate cancer - Males	33
Number of pathology samples indicating gynaecological cancer - Females	35
Number of pathology samples indicating upper gastrointestinal cancer - All persons	37
Number of pathology samples indicating head & neck cancer - All persons	39
Number of pathology samples indicating urinary cancer - All persons	41
Number of pathology samples indicating haematological cancer - All persons	43
Number of pathology samples indicating malignant melanoma - All persons	45
Number of pathology samples indicating non-melanoma skin cancer - All persons	47
Number of pathology samples indicating other cancer - All persons	49
Notes	51

SUMMARY Recent trends in the number of pathology samples indicating cancer: Nov 2020

- 1) This summary provides an overview of recent trends in the number of pathology samples indicating cancer (excluding non-melanoma skin cancer, NMSC) which were taken from 1st January 2020 to the week ending 14th November 2020 in Northern Ireland.
- 2) These trends are contrasted with the annual average number of pathology samples indicating cancer (ex NMSC) during 2017-2019 in order to provide an indication of the potential impact of the Covid-19 restrictions on diagnostic cancer services.
- 3) Data are sourced from the four NHS pathology laboratories in Northern Ireland (Belfast, Altnagelvin, Antrim, Craigavon), which are usually provided to the NI Cancer Registry on a monthly basis.

Trends in number of pathology samples indicating cancer by week first sample taken



Week sample first taken (End date in 2020)

Percentage change between 2017-2019 and 2020 in the number of pathology samples indicating cancer, taken in weeks 42-46 of each year (11 October to 14 November in 2020)


5) Patient demographics

There was an 18% reduction in the number of pathology samples indicating cancer in weeks 42-46 of 2020, compared to the average value for weeks 42-46 in 2017-2019. In particular, there was an 18% decrease among males and females. A decrease of 20% occurred in the number of samples among patients aged 0-69 years, while a decrease of 15% occurred among those aged 70 and older. Reductions were greatest in Antrim (30%) and Craigavon (31%), but decreases were also recorded in Belfast (11%) and Altnagelvin (16%).


6) Cancer type

Compared to the annual average for weeks 42-46 in 2017-2019, the number of pathology samples indicating bowel cancer in 2020 decreased by 15%, while those indicating prostate cancer decreased by 6%. Reductions were greatest for haematological and urinary cancers. Only, the number of pathology samples indicating gynacological cancer increased between 2017-2019 and 2020.







Number of pathology samples indicating cancer (ex NMSC): All persons




*Date week ended in 2020




Number of pathology samples indicating cancer (ex NMSC): Males



*Date week ended in 2020



Number of pathology samples indicating cancer (ex NMSC): Females




Month change average -26% Aug Sep -10% Oct -28% Nov* -25%


* Part only - Up to week 46

						Feb 2019
By week sample ta	ken					Mar 2019
			Five-w	veek rollin	g total	Apr 2019
Week number*	2017-2019	2020	2017-2019	2020	Percentage	May 2019
Maak 22 (00 Aug)	average	101	average		change	Jun 2019
Week 32 (08 Aug)	201	121				Jul 2019
Week 33 (15 Aug)	174	166				Aug 2019
Week 34 (22 Aug)	178	154				Sep 2019
Week 35 (29 Aug)	159	155				Oct 2019
Week 36 (05 Sep)	213	123	925	719	-22%	Nov 2019
Week 37 (12 Sep)	186	175	909	773	-15%	Dec 2019
Week 38 (19 Sep)	185	133	920	740	-20%	Jan 2020
Week 39 (26 Sep)	203	154	945	740	-22%	Feb 2020
Week 40 (03 Oct)	206	189	992	774	-22%	Mar 2020
Week 41 (10 Oct)	188	156	967	807	-17%	Apr 2020
Week 42 (17 Oct)	186	141	967	773	-20%	May 2020
Week 43 (24 Oct)	197	144	980	784	-20%	Jun 2020
Week 44 (31 Oct)	166	143	943	773	-18%	Jul 2020
Week 45 (07 Nov)	180	161	917	745	-19%	Aug 2020
Week 46 (14 Nov)	169	146	899	735	-18%	Sep 2020
*Date week ended in 2	020					Oct 2020

Samples



Number of pathology samples indicating cancer (ex NMSC): Ages 0 to 69




By month and year sample taken

Samples


Month	2017-2019	2020	Percentag	
	average	2020	change	
Aug	775	583	-25%	
Sep	798	680	-15%	
Oct	854	616	-28%	
Nov*	394	284	-28%	

* Part only - Up to week 46


By week sample t	<u>aken</u>					Mar 2019
		Five-w	Five-week rolling total			
Week number*	2017-2019 average	2020	2017-2019 average	2020	Percentage change	May 2019 Jun 2019
Week 32 (08 Aug)	197	127				Jul 2019
Week 33 (15 Aug)	174	164				Aug 2019
Week 34 (22 Aug)	170	146				Sep 2019
Week 35 (29 Aug)	148	143				Oct 2019
Week 36 (05 Sep)	204	128	892	708	-21%	Nov 2019
Week 37 (12 Sep)	191	167	886	748	-16%	Dec 2019
Week 38 (19 Sep)	176	126	887	710	-20%	Jan 2020
Week 39 (26 Sep)	203	135	921	699	-24%	Feb 2020
Week 40 (03 Oct)	193	177	967	733	-24%	Mar 2020
Week 41 (10 Oct)	190	147	953	752	-21%	Apr 2020
Week 42 (17 Oct)	180	136	942	721	-23%	May 2020
Week 43 (24 Oct)	201	132	968	727	-25%	Jun 2020
Week 44 (31 Oct)	157	150	922	742	-19%	Jul 2020
Week 45 (07 Nov)	178	153	906	718	-21%	Aug 2020
Week 46 (14 Nov)	162	131	878	702	-20%	Sep 2020
*Date week ended in .	2020					Oct 2020




Number of pathology samples indicating cancer (ex NMSC): Ages 70 and over



*Date week ended in 2020



Number of pathology samples indicating cancer (ex NMSC): Belfast laboratory




By month sample taken

Month	2017-2019 average	2020	Percentage change
Aug	764	580	-24%
Sep	707	652	-8%
Oct	802	594	-26%
Nov*	365	306	-16%


* Part only - Up to week 46

By week sample ta	<u>aken</u>					Mar 2019
			Five-week rolling total			Apr 2019
Week number*	2017-2019 average	2020	2017-2019 average	2020	Percentage change	May 2019 Jun 2019
Week 32 (08 Aug)	187	118				Jul 2019
Week 33 (15 Aug)	171	148				Aug 2019
Week 34 (22 Aug)	170	154				Sep 2019
Week 35 (29 Aug)	149	157				Oct 2019
Week 36 (05 Sep)	180	119	857	696	-19%	Nov 2019
Week 37 (12 Sep)	168	142	838	720	-14%	Dec 2019
Week 38 (19 Sep)	163	117	830	689	-17%	Jan 2020
Week 39 (26 Sep)	176	164	835	699	-16%	Feb 2020
Week 40 (03 Oct)	200	169	886	711	-20%	Mar 2020
Week 41 (10 Oct)	185	137	890	729	-18%	Apr 2020
Week 42 (17 Oct)	163	123	885	710	-20%	May 2020
Week 43 (24 Oct)	177	141	900	734	-18%	Jun 2020
Week 44 (31 Oct)	134	136	858	706	-18%	Jul 2020
Week 45 (07 Nov)	174	170	833	707	-15%	Aug 2020
Week 46 (14 Nov)	147	136	795	706	-11%	Sep 2020
*Date week ended in 2	2020					Oct 2020

Samples



Number of pathology samples indicating cancer (ex NMSC): Altnagelvin laboratory



Trend in number of pathology samples indicating cancer by month and year sample taken


H H H	ug 2020 Oct 2020	Month/Year	Samples
		Oct 2018	247
		Nov 2018	198
		Dec 2018	157
		Jan 2019	229
		Feb 2019	191
		Mar 2019	211
ek rollin	ig total	Apr 2019	243
2020	Percentage	May 2019	253
2020	change	Jun 2019	170
		Jul 2019	211
		Aug 2019	170
		Sep 2019	189
		Oct 2019	225
177	-10%	Nov 2019	199
207	2%	Dec 2019	136
195	-12%	Jan 2020	205
199	-12%	Feb 2020	207
202	-13%	Mar 2020	166
205	-12%	Apr 2020	92
200	-15%	May 2020	110
202	-16%	Jun 2020	126
204	-19%	Jul 2020	142
216	-13%	Aug 2020	144
208	-16%	Sep 2020	200

Oct 2020


*Date week ended in 2020


Week 45 (07 Nov)

Week 46 (14 Nov)




Number of pathology samples indicating cancer (ex NMSC): Antrim laboratory





Number of pathology samples indicating cancer (ex NMSC): Craigavon laboratory



Week 42 (17 Oct)

Week 43 (24 Oct)

Week 44 (31 Oct)

Week 45 (07 Nov)

Week 46 (14 Nov)

*Date week ended in 2020

Trend in number of pathology samples indicating cancer by month and year sample taken

-18%

-24%

-25%

-25%

-29%

-31%

Apr 2020

May 2020

Jun 2020


Jul 2020

Aug 2020


Sep 2020


Oct 2020

Samples





Number of pathology samples indicating bowel cancer: All persons







Number of pathology samples indicating bowel cancer: All persons, screening age (60-74)







Number of pathology samples indicating lung cancer: All persons







Number of pathology samples indicating breast cancer: Females






Number of pathology samples indicating breast cancer: Females, screening age (50-70)






Number of pathology samples indicating prostate cancer: Males




Note: (ICD10 codes: C61).

*Date week ended in 2020


Samples




Number of pathology samples indicating gynaecological cancer: Females







Number of pathology samples indicating upper gastrointestinal cancer: All persons



Note: Includes oesophagus and stomach (ICD10 codes: C15, C16).

*Date week ended in 2020

Week 46 (14 Nov)

Oct 2020


44

4


50


47

-7%





Number of pathology samples indicating head & neck cancer: All persons







Number of pathology samples indicating urinary cancer: All persons









Number of pathology samples indicating haematological cancer: All persons





Number of pathology samples indicating malignant melanoma: All persons




2% Aug Sep -10% Oct -46% Nov* -5%

* Part only - Up to week 46


By week sample taken Five-week rolling total						Feb 2019 Mar 2019 Apr 2019
Week number*	2017-2019 average	2020	2017-2019 average	2020	Percentage change	May 2019 Jun 2019
Week 32 (08 Aug)	10	6				Jul 2019
Week 33 (15 Aug)	12	14				Aug 2019
Week 34 (22 Aug)	15	13				Sep 2019
Week 35 (29 Aug)	5	12				Oct 2019
Week 36 (05 Sep)	11	8	52	53	1%	Nov 2019
Week 37 (12 Sep)	10	10	53	57	8%	Dec 2019
Week 38 (19 Sep)	13	9	54	52	-3%	Jan 2020
Week 39 (26 Sep)	12	9	51	48	-6%	Feb 2020
Week 40 (03 Oct)	12	8	58	44	-24%	Mar 2020
Week 41 (10 Oct)	13	7	60	43	-29%	Apr 2020
Week 42 (17 Oct)	15	9	66	42	-36%	May 2020
Week 43 (24 Oct)	10	4	62	37	-41%	Jun 2020
Week 44 (31 Oct)	9	8	60	36	-40%	Jul 2020
Week 45 (07 Nov)	10	15	58	43	-25%	Aug 2020
Week 46 (14 Nov)	12	10	56	46	-18%	Sep 2020
*Date week ended in 2020						Oct 2020

Samples

Note: (ICD10 code: C43).



Number of pathology samples indicating non-melanoma skin cancer: All persons



174

165

148

138

172

122

Trend in number of pathology samples indicating cancer by month and year sample taken

Note: (ICD10 code: C44).

*Date week ended in 2020

Week 41 (10 Oct)

Week 42 (17 Oct)

Week 43 (24 Oct)

Week 44 (31 Oct)

Week 45 (07 Nov)

Week 46 (14 Nov)

Oct 2020

615

147

159

141

118

147

138

865

850

814

787

798

746

700

732

737

697

712

703

-19%


-14%

-9%


-11%

-11%

-6%



Number of pathology samples indicating other cancer: All persons



Notes:

1. NMSC: Non-melanoma skin cancer

2. Data is sourced from the four NHS pathology laboratories in Northern Ireland (Altnagelvin, Antrim, Belfast, Craigavon), which is provided to the NI Cancer Registry on a monthly basis. It does not include information on pathology samples processed by private laboratories.

3. Figures represent the number of pathology samples taken in the given week/month which indicated a malignant tumour and had this result coded and recorded by the end of November 2020. Further samples taken during Jan-Nov may not yet have been recorded as a result was not available by the end of November 2020. The presented figures may thus represent an undercount, particularly for later weeks. However, when comparisons are made with 2017-2019 the same limitation has been applied to all years in order to maintain comparability.

4. Assignment of week number is based upon a Sunday to Saturday week. The week ending label used in graphs and tables is based upon the date of the end of the week in 2020. This is compared with the equivalent Sunday-Saturday week in previous years, although the actual date ending this week in previous years will differ.

5. Individual patients with cancer may have more than one pathology sample. A diagnosis of cancer may be a result of more than one procedure indicating cancer, for example a breast cancer diagnosis may be based upon a positive biopsy of the breast and then a separate positive dissection of a lymph node. The presented number of cancer samples does not therefore represent the number of people with pathologically diagnosed cancer, but does indicate the processing workload of Northern Ireland's NHS pathology laboratories for new cancer cases.

Acknowledgements

The Northern Ireland Cancer Registry (NICR) is funded by the Public Health Agency. NICR uses data provided by patients and collected by the health service as part of their care and support.

Further Information

Further data is available at: **www.qub.ac.uk/nicr** Phone: +44 (0)28 9097 6028 e-mail: nicr@qub.ac.uk

